Physician profile
Sunil Momin
NPI 1780039677
$1,113.87
in general payments reported to CMS, 2019-2025
14 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.01 · 2022: $178 · 2023: $323 · 2024: $221 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $374.48 | 2020-2023 | Cardiomems |
| Amgen INC. | $132.53 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $131.51 | 2024-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $108.47 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $88.85 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $65.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $51.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $36.21 | 2023-2025 | Arexvy, Shingrix |
| Boston Scientific Corporation | $27.65 | 2024 | Greenlight Xps |
| Biogen, INC. | $24.13 | 2025 | Spinraza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.46 | 2023 | Jardiance |
| Sanofi Pasteur INC. | $21.10 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.39 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Momin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.